Mustang Bio Balance Sheet Health

Financial Health criteria checks 6/6

Mustang Bio has a total shareholder equity of $3.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $14.9M and $11.3M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$14.23m
EquityUS$3.61m
Total liabilitiesUS$11.30m
Total assetsUS$14.91m

Recent financial health updates

Recent updates

Mustang Bio: This Horse May Gallop Still

Sep 23

Is Mustang Bio, Inc. (NASDAQ:MBIO) Trading At A 46% Discount?

Aug 09
Is Mustang Bio, Inc. (NASDAQ:MBIO) Trading At A 46% Discount?

Mustang Bio: The Market Is Missing This Opportunity

May 03

Will Mustang Bio (NASDAQ:MBIO) Spend Its Cash Wisely?

Dec 29
Will Mustang Bio (NASDAQ:MBIO) Spend Its Cash Wisely?

Mustang Bio: Remains Underfollowed Despite Moving Closer To Pivotal Studies

Sep 14

Financial Position Analysis

Short Term Liabilities: MBIO's short term assets ($14.9M) exceed its short term liabilities ($11.2M).

Long Term Liabilities: MBIO's short term assets ($14.9M) exceed its long term liabilities ($150.0K).


Debt to Equity History and Analysis

Debt Level: MBIO is debt free.

Reducing Debt: MBIO has no debt compared to 5 years ago when its debt to equity ratio was 29.9%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MBIO has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MBIO has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 2% each year.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/19 22:14
End of Day Share Price 2025/05/19 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Mustang Bio, Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Justin ZelinB. Riley Securities, Inc.
Jonathan AschoffB. Riley Wealth